Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (opent nieuw venster)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Bron‎: Cancer 2013;119(21):3784-7.

Geïndexeerd‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (opent nieuw venster)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (opent nieuw venster)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Bron‎: Lancet 1989;334(8655):122-4.

Geïndexeerd‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (opent nieuw venster)

Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. (opent nieuw venster)

Ben-Bassat I, Douer D, Ramot B.

Bron‎: Eur J Haematol 1990;45(2):86-9.

Geïndexeerd‎: PubMed 2209824

https://www.ncbi.nlm.nih.gov/pubmed/2209824 (opent nieuw venster)

Fibrinolytic inhibitors for cancer-associated bleeding problems. (opent nieuw venster)

Dean A, Tuffin P.

Bron‎: J Pain Symptom Manage 1997;13(1):20-4.

Geïndexeerd‎: PubMed 9029858

https://www.ncbi.nlm.nih.gov/pubmed/9029858 (opent nieuw venster)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (opent nieuw venster)

Ford PA, Grant SJ, Mick R, Keck G.

Bron‎: J Clin Oncol 2015;33(15):1674-9.

Geïndexeerd‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (opent nieuw venster)

Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. (opent nieuw venster)

Garewal HS, Durie BG.

Bron‎: Scand J Haematol 1985;35(5):497-500.

Geïndexeerd‎: PubMed 4089529

https://www.ncbi.nlm.nih.gov/pubmed/4089529 (opent nieuw venster)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (opent nieuw venster)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Bron‎: Cancer 2006;107(1):136-40.

Geïndexeerd‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (opent nieuw venster)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (opent nieuw venster)

Marshall A, Li A, Drucker A, Dzik W.

Bron‎: Hematol Oncol 2016;34(3):147-53.

Geïndexeerd‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (opent nieuw venster)

Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. (opent nieuw venster)

Prokopchuk-Gauk O, Brose K.

Bron‎: Cureus 2015;7(12):e428.

Geïndexeerd‎: PubMed 26848417

DOI‎: 10.7759/cureus.428

https://www.ncbi.nlm.nih.gov/pubmed/26848417 (opent nieuw venster)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (opent nieuw venster)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Bron‎: Leuk Lymphoma 1995;19(1-2):141-4.

Geïndexeerd‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (opent nieuw venster)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (opent nieuw venster)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Bron‎: Hematol Oncol 2008;26(4):241-6.

Geïndexeerd‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (opent nieuw venster)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (opent nieuw venster)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Bron‎: Am J Hematol 2006;81(9):720.

Geïndexeerd‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (opent nieuw venster)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (opent nieuw venster)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Bron‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Geïndexeerd‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (opent nieuw venster)

The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. (opent nieuw venster)

Erduran E, Bahadir A, Mutlu M.

Bron‎: Eur J Clin Med Oncol 2011;3(5):1-4.

Geïndexeerd‎: EMBASE 2012295551

https://www.worldcat.org/title/european-journal-of-clinical-medical-oncology/oclc/645421559&referer=brief_results (opent nieuw venster)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (opent nieuw venster)

Franchini M, Veneri D, Lippi G.

Bron‎: Bone Marrow Transplant 2007;39(12):729-35.

Geïndexeerd‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (opent nieuw venster)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (opent nieuw venster)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Bron‎: Am J Hematol 2002;69(3):219-22.

Geïndexeerd‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (opent nieuw venster)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (opent nieuw venster)

Hsieh A, Cheong I.

Bron‎: Am J Emerg Med 2007;25(9):1085.e1-2.

Geïndexeerd‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (opent nieuw venster)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (opent nieuw venster)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Bron‎: Haemostasis 1996;26 Suppl 1:159-64.

Geïndexeerd‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (opent nieuw venster)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (opent nieuw venster)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Bron‎: Med Oncol 2010;27(1):16-9.

Geïndexeerd‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (opent nieuw venster)

Recombinant factor VIIa for bleeding in refractory thrombocytopenia. (opent nieuw venster)

Vidarsson B, Önundarson PT.

Bron‎: Thromb Haemost 2000;83(4):634-5.

Geïndexeerd‎: PubMed 10780334

https://www.ncbi.nlm.nih.gov/pubmed/10780334 (opent nieuw venster)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (opent nieuw venster)

Zver S, Andoljšek D, Černelč P.

Bron‎: Eur J Haematol 2004;72(6):455-6.

Geïndexeerd‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (opent nieuw venster)

Management of bleeding complications of hematologic malignancies. (opent nieuw venster)

Green D.

Bron‎: Semin Thromb Hemost 2007;33(4):427-34.

Geïndexeerd‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (opent nieuw venster)

Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. (opent nieuw venster)

Harrington DJ, Booth L, Dando N, Cottingham L, Beynon T.

Bron‎: Int J Lab Hematol 2013;35(4):457-9.

Geïndexeerd‎: PubMed 23216984

DOI‎: 10.1111/ijlh.12035

https://www.ncbi.nlm.nih.gov/pubmed/23216984 (opent nieuw venster)

Management of bleeding in patients with advanced cancer. (opent nieuw venster)

Pereira J, Phan T.

Bron‎: Oncologist 2004;9(5):561-70.

Geïndexeerd‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (opent nieuw venster)

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (opent nieuw venster)

Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F.

Bron‎: Haematologica 1997;82(5):584-7.

Geïndexeerd‎: PubMed 9407726

https://www.ncbi.nlm.nih.gov/pubmed/9407726 (opent nieuw venster)

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (opent nieuw venster)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Bron‎: Bull Cancer 2006;93(2):E7-12.

Geïndexeerd‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (opent nieuw venster)